Other languages CEL-SCI Corporation

Equities

CVM

US1508376076

Real-time Estimate Cboe BZX Other stock markets 02:00:20 2024-05-06 pm EDT			5-day change	1st Jan Change
1.705 ^USD	+4.60%		+23.40%	-36.03%

Apr. 23	CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	CI
Feb. 14	CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	Apr. 23
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	Feb. 14
Cel-Sci Prices $7.8 Million Public Offering of Common Shares	Feb. 09
CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	Feb. 06
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	Jan. 31
Sector Update: Health Care Stocks Gain in Afternoon Trading	Jan. 31
Cel-Sci Receives Pediatric Requirements Waiver for Multikine From European Medicines Agency	Jan. 31
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 21
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	Dec. 05
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals	23-10-24
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-23
Sector Update: Health Care	23-10-23
Top Midday Gainers	23-10-23
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain	23-10-23
CEL-SCI Corporation Readies Its Multikine Manufacturing Facility for Commercial Scale Production	23-10-19
Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer	23-10-05
Cel-Sci Submits Scientific Advice Filing to European Medicines Agency for Multikine in the Treatment of Head & Neck Cancer	23-09-26
CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10
Cel-Sci Closes $5 Million Public Offering; Shares Drop	23-07-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CEL-SCI Corporation

Equities

CVM

US1508376076

Other languages

Filters